© 2017 Pharmstandard Ventures
Jounce Therapeutics
(NASDAQ:JNCE)
Cambridge, MA, USA
Year of Investment: 2015
Strategic Deal with Celgene in July, 2016
IPO in January, 2017
IPO in January, 2017
Jounce
Therapeutics
(NASDAQ:JNCE)
Cambridge, MA, USA
Year of Investment: 2015
Strategic Deal with Celgene in July, 2016
IPO in January, 2017
IPO in January, 2017
Jounce Therapeutics is developing novel cancer immunotherapies with the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Jounce utilizes translational science insights to match the right targets to well defined patient populations in order to achieve a higher probability of success and rapid proof-of-concept. The company is pursuing programs against multiple targets in the T cell checkpoint area, as well as programs beyond T cell checkpoints, where current immunotherapies are less likely to be effective. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with initial funding from leading life sciences investor, Third Rock Ventures.
For more information, please visit:
www.jouncetx.com
For more information, please visit:
www.jouncetx.com
Jounce Latest News
07.19.2021
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
15.09.2021
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
Read more news >
07.19.2021
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
15.09.2021
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
Read more news >
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally